ABSTRACT
INTRODUCTION Lipids are critical in coronary atherosclerosis, making lipid reduction essential for prevention of cardiovascular disease. Achieving guideline-recommended LDL cholesterol (LDL-C) targets remains challenging for patients with and without diabetes. This study aims to compare clinical differences between STEMI patients with and without diabetes and evaluate lipid-lowering strategies on admission and on discharge.
METHODS Retrospective study on STEMI patients admitted to our center between 2021 and 2023. Data included anthropometric details, lipid profiles, cardiovascular risk scores and drug therapy. Theoretical LLT potency allowed computation of LDL-C levels as if they hadn’t undergone any LLT therapy (wild LDL-C).
RESULTS Of 467 screened patients, 443 were included, with 72 having diabetes. Statistically significant differences were observed in hypertension (72.2% vs. 56.3%, p < 0.001) and peripheral arterial disease prevalence (15.2% vs. 6.2%, p = 0.01). Non-diabetic patients had higher total cholesterol, HDL-C, and LDL-C levels but similar wild LDL-C (110.7 mg/dL vs. 117.5 mg/dL, p = 0.30). At admission, 50.0% (diabetic) and 81.1% (non-diabetic) did not achieve LDL-C targets (p < 0.001). At discharge, 31.9% (diabetic) and 36.6% (non-diabetic) were discharged without sufficient LLT to achieve target cholesterol levels (p < 0.001).
CONCLUSION A significant proportion of patients, especially those with diabetes, failed to attain recommended LDL-C targets at STEMI admission. Aggressive lipid-lowering interventions, in particular with the support of electronic tools to assess LLT potency, are crucial for prompt LDL-C target attainment.
Highlights
At admission significant proportion of STEMI patients, including those with diabetes, fail to achieve LDL-C targets for their risk class in primary prevention.
Limited adoption of combination therapies with ezetimibe.
High-potency statins commonly prescribed at discharge, but many patients forecasted not to achieve LDL-C targets.
Tailored treatment regimens utilizing electronic tools crucial for prompt attainment of LDL-C targets post-STEMI.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Comitato etico per la Sperimentazione Clinica (CESC) Verona
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
All authors have seen and approved the manuscript.
Data Availability
All data produced in the present work are contained in the manuscript